Biotech Nektar raises $460M selling new shares and warrants

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $460 million of…

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Open the article to view the coverage from THE TIMES OF BENGAL

Biotech Nektar raises $460M selling new shares and warrants

Underwriters fully exercise their option as Nektar sells 7.64M shares at $58 plus 293,103 pre-funded warrants, bringing gross proceeds to about $460M.